Endometrial cancer incidence is rapidly rising globally, and in recent years, research has gained significant momentum. Surgical techniques, histopathology classification, risk stratification and understanding of different adjuvant modalities have progressed a great deal since the last endometrial cancer FIGO (The International Federation of Gynecology and Obstetrics) staging revision in 2009.1 Simultaneous rapid advances in the development of targeted therapies, accompanied by improved molecular and genetic diagnostics have contributed to a significant change in our understanding of the disease.

Department of Obstetrics and Gynaecology and Gynaecological Oncology Unit, University of Pretoria, South Africa

Department of Obstetrics and Gynaecology and Gynaecological Oncology Unit, University of Pretoria, South Africa

License By submitting manuscripts to SAJGO, authors of original articles are assigning copyright to the South African Society of Gynaecologic Oncology (SASGO). Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJGO for educational and research purposes without obtaining permission.